

KELLERHALS CARRARD ADVISES MODERNA SWITZERLAND ON COVID-19 VACCINATION

Posted on 15 February 2021



Category: [News](#)

Tags: [Claudia Götz Staehelin](#), [Ex-Featured](#), [Kellerhals Carrard](#), [Nicolas Mosimann](#), [Oliver M. Brupbacher](#)



Kellerhals Carrard, under the responsibility of partners Claudia Götz Staehelin (pictured), Oliver M. Brupbacher and Nicolas Mosimann, [advised Moderna](#) on legal and regulatory aspects related to the establishment of its supply chain for its COVID-19 Vaccine and Swiss launch preparations, including trade compliance and regulatory aspects.

Moderna is pioneering a new class of drugs, the messenger RNA Therapeutics (mRNAs), with the potential to treat a wide range of diseases and conditions. Moderna developed a vaccine against Covid-19 for which Swissmedic granted a temporary marketing authorization on 12 January 2021 under the name „COVID-19 Vaccine Moderna“ following the scientific assessment of Swissmedic.